Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.
BACKGROUND
Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.


METHODS
A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.


CONCLUSIONS
Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.
Monk
Bradley J
BJ
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA.
Choi
David C
DC
Pugmire
Gordon
G
Burger
Robert A
RA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab